In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models. by Grafinger, Katharina Elisabeth et al.
 This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1002/dta.2446 
 
This article is protected by copyright. All rights reserved. 
In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe 
using microsomal and microbial models 
Katharina Elisabeth Grafinger 1,2, Katja Stahl 3, Andreas Wilke 3, Stefan König 1, Wolfgang Weinmann 1 
1
 Institute of Forensic Medicine, Forensic Toxicology and Chemistry, University of Bern, Bühlstrasse 
20, 3012 Bern, Switzerland 
2 Graduate School for Cellular and Biomedical Sciences, University of Bern, Freiestrasse 1, 3012 Bern, 
Switzerland 
3Department of Mechanical and Process Engineering, University of Applied Sciences Offenburg, 
Badstrasse 24, 77652 Offenburg, Germany 
*corresponding author: Katharina Elisabeth Grafinger, Katharina.grafinger@irm.unibe.ch Institute of 
Forensic Medicine, Bühlstrasse 20, 3012 Bern, Switzerland  
Metabolism; NBOMe; NPS; pHLM; fungi Cunninghamella elegans; metabolism 
 
Abstract:  
Numerous 2,5-dimethoxy-N-benzylphenethylamines (NBOMe), carrying a variety of lipophilic 
substituents at the 4-position, are potent agonists at 5-hydroxytryptamine (5HT2A) receptors and 
show hallucinogenic effects. The present study investigated the metabolism of 25D-NBOMe, 25E-
NBOMe and 25N-NBOMe using the microsomal model of pooled human liver microsomes (pHLM) 
and the microbial model of the fungi Cunninghamella elegans (C. elegans). Identification of 
metabolites was performed using liquid chromatography-high resolution-tandem mass spectrometry 
(LC-HR-MS/MS) with a QqToF instrument. In total, 36 25D-NBOMe phase I metabolites, 26 25E-
NBOMe phase I metabolites and 24 25N-NBOMe phase I metabolites were detected and identified in 
pHLM. Furthermore, 14 metabolites of 25D-NBOMe, eleven 25E-NBOMe metabolites and nine 25N-
NBOMe metabolites could be found in C. elegans. The main biotransformation steps observed were 
oxidative deamination, oxidative N-dealkylation also in combination with hydroxylation, oxidative O-
demethylation possibly combined with hydroxylation, oxidation of secondary alcohols, mono- and 
dihydroxylation, oxidation of primary alcohols and carboxylation of primary alcohols. Additionally, 
oxidative di-O-demethylation for 25E-NBOMe and reduction of the aromatic nitro group and N-
acetylation of the primary aromatic amine for 25N-NBOMe took place. The resulting 25N-NBOMe 
metabolites were unique for NBOMe compounds. For all NBOMes investigated, the corresponding 
2,5-dimethoxyphenethylamine (2C-X) metabolite was detected. This study reports for the first time 
25X-NBOMe N-oxide metabolites and hydroxylamine metabolites, which were identified for 25D-
NBOMe and 25N-NBOMe and all three investigated NBOMes, respectively. C. elegans was capable of 
generating all main biotransformation steps observed in pHLM and might therefore be an interesting 
model for further studies of new psychoactive substances (NPS) metabolism.  
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1. Introduction:  
In the last ten years, new psychoactive substances (NPS) have become a growing problem. Chatwin 
et al. 1 define NPS as “chemical compounds that have been modified and developed to mimic the 
effects of drugs which are already prohibited”. Currently, the European Union (EU) Early Warning 
System, coordinated by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), is 
monitoring over 620 NPS, with one sixth of them belonging to the chemical class of 
phenethylamines2, 3. Prominent substances belonging to this class are 2C-type phenethylamines 4, 
which are 2,5-dimethoxyphenethylamines, substituted at the 4-position, typically with halogens or 
alkyl groups, and also 2,5-dimethoxy-N-benzylphenethylamines, so called NBOMes which have 
emerged in recent years 5. Substitutions on the 4-position include bromine (25B-NBOMe), chlorine 
(25C-NBOMe), methyl (25D-NBOMe), ethyl (25E-NBOMe), iodine (25I-NBOMe), nitro (25N-NBOMe) 
groups but the unsubstituted form (25H-NBOMe) is also available 6, which has been detected as an 
impurity in blotter papers 7. These substances were found to be potent 5HT2A receptor agonists 8-11. 
Furthermore, Braden et al. could show that the addition of the N-methoxybenzyl group to 2C-X 
compounds significantly increases their affinity to the 5-HT2A receptor and therefore results in higher 
behavioural responses 12. NBOMes and their homologues produce psycho- and cardiovascular 
stimulant effects in addition to hallucinations 13. In cases of acute drug intoxication, 
sympathomimetic toxicity such as tachycardia, hypertension, mydriasis, agitation, vasoconstriction 
and hyperthermia were observed 14-17, which could point towards serotonin syndrome. 
Recommended treatment in case of intoxication is heart rate, blood pressure and body temperature 
monitoring 18. Furthermore, for acute treatment of sympathomimetic toxidrome, administration of 
benzodiazepines, fluid replacement and physical cooling should be performed to control agitation, 
cardiovascular stimulation and hyperthermia due to serotonin toxicity 16, 18, 19. NBOMe compounds 
are usually taken in doses of 200 µg to 2000 µg (depending on the compound), mainly by sublingual 
application on blotter papers, and they have been reported to be sold as counterfeit LSD products 20, 
21. Several NBOMe case studies of intoxication with non-fatal 15, 16, 22 and fatal intoxication 13, 23, 24 
have been reported. The presence of metabolites is proof of consumption of the parent substrate. 
Therefore, metabolism studies are needed to identify metabolites of NPS, which can then be used as 
biomarkers to confirm consumption. Another issue concerning NPS is the lack of reference 
standards, which can be overcome by identifying unique fingerprints of drug metabolites. 
In order to form phase I and phase II metabolites, different in vivo and in vitro models are available. 
Human studies are ethically not favourable and therefore animal in vivo studies or in vitro 
alternatives are commonly used. Pooled human liver microsomes (pHLM) have been shown to be a 
reliable in vitro model for the generation of phase I metabolites 25-27. An alternative to in vitro 
models, such as primary human hepatocytes (PHH), pooled human S9 fraction (pS9) or pHLM 28, are 
microbial models of the fungus Cunninghamella elegans (C. elegans). Microbial models have the 
advantage of low cost, easy handling, scale-up capability and further to reduce use of animals 29. 
Moreover, C. elegans has the enzymatic activity of both phase I and II enzymes 29 and holds the 
cytochrome P450 CYP509A1 enzyme 30. This class of fungi has the ability to facilitate reactions such 
as hydroxylation, carboxylation, dihydrodiol formation, oxidative defluorination, N-dealkylation, 
glucuronidation and sulfation 31, 32, as well as those catalysed by human CYP1A2, CYP2C9, CYP2C19, 
CYP2D6 and CYP3A4 29, 32-34. It was recently shown by Nielsen et al. 35 that the main enzymes involved 
in the 25I-NBOMe metabolism are CYP3A4 and CYP2D6. Caspar et al. 4 reported that for 25B-NBOMe 
and 25C-NBOMe the enzymes CYP1A2, CYP3A4, CYP2C9 and CYP2C19 play a crucial role.  
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The aim of the present study was to conduct metabolism studies of three different NBOMe 
analogues, 25D-NBOMe, 25E-NBOMe and 25N-NBOMe employing pHLM and C. elegans and to 
identify phase I metabolites based on mass spectrometric data. Besides the most common 
analogues 25B-NBOMe and 25I-NBOMe, the three analogues have previously been identified on 
confiscated blotter papers 7. All measurements were performed using liquid chromatography-high 
resolution-tandem mass spectrometry (LC-HR-MS/MS) and metabolites were identified according to 
their precursor masses, the most abundant product ions and the isotope patterns. So far no 
biotransformation data are available on the three investigated NBOMes.  
2. Materials and Methods 
2.1 Chemicals and Reagents 
Yeast extract, malt extract and peptone from soy beans were obtained from Carl Roth (Karlsruhe, 
Germany), glucose from Applichem (Darmstadt, Germany). C. elegans strain DMSZ 1908 was 
obtained from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures 
(Braunschweig, Germany). Sodium hydroxide, magnesium chloride and di-
sodiumhydrogenphosphate-dihydrate were purchased from Merck AG (Zug, Switzerland), 
sulfosalicylic acid and superoxide dismutase (6016 units/mg protein) from Sigma Aldrich (Buchs, 
Switzerland). Pooled human S9 fraction (pS9) (150 donors, 20 mg/mL), pooled human liver 
microsomes (pHLM) (150 donors, 20 mg/mL), NADPH-regenerating solutions A/B , UGT-reaction mix 
A/B and 0.5 M potassium phosphate buffer pH 7.4 were obtained from Corning (New York, NY, USA). 
Hydrochloride salts of 25D-NBOMe (98.5 %), 25E-NBOMe (>98.5 %), and 25N-NBOMe (98.5 %), were 
purchased from Lipomed (Arlesheim, Switzerland). The reference standard of 25B-NBOMe-D3 (0.01 
mg/mL in methanol) was obtained from Cerilliant (Round Rock, TX, USA). Formic acid (analytical 
grade, 98 %) and ammonium formate were obtained from Fluka (Sigma-Aldrich, Buchs, Switzerland), 
methanol (absolute, HPLC grade) from Biosolve (Chemie Brunschwig, Basel, Switzerland), acetonitrile 
(HPLC gradient grade, 99.9 %) and 1-chlorobutane (HPLC gradient grade, 99.8 %) from Acros 
Organics (Chemie Brunschwig, Basel, Switzerland). Direct-Q water purification system from Millipore 
(Zug, Switzerland) was used to produce in-house ultrapure water. All solutions and samples were 
handled using precision pipettes from Gilson (Mettmenstetten, Switzerland) and Socorex Isba S.A 
(Ecublens, Switzerland) 
2.2 In Silico predictions 
Prediction of possible metabolites was carried out in order to assist in the interpretation of the 
collected mass spectrometric data, using Meteor Nexus v.3.0.1 (Lhasa Limited). It is a knowledge-
based expert system that predicts the biotransformation of a substrate 36. Parameters were as 
follows: species human, processing direction breath first, maximal depth 3, absolute reasoning: 
minimum likelihood equivocal and relative reasoning: level of cut-off 2. Results of the in silico 
predictions were compared to information independent LC-HR-MS/MS measurements using the 
Analyst software 1.6 TF with MasterViewTM Software Version 1.1 with the extracted ion current (XIC) 
tool.  
2.3 Microsomal assay using pHLM   
For generating phase I metabolites, microsomal in vitro experiments were performed as previously 
published 27. Briefly, the following components were mixed in a reaction tube, with a final volume of 
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50 µL and indicated concentrations are final concentrations: deionized water, potassium phosphate 
buffer (100 mM), magnesium chloride (5 mM), superoxide dismutase (200 units/mL), NADPH-
regenerating solution A (NADP+ and glucose-6-phosphate) and B (glucose-6-phosphate 
dehydrogenase), pHLM (1 mg/mL) and a reference standard of one of the three investigated 
NBOMes (25 µM). Samples were incubated for 60 min at 37 °C, which is an commonly reported 
incubation time in literature. Simultaneously, blanks containing no drug substrates and negative 
controls containing no pHLM were prepared. The reactions were stopped by adding 50 µL ice cold 
acetonitrile containing an internal standard of 25B-NBOMe-D3. After mixing, the samples were 
centrifuged at 17‘ 000 g and 8 °C for 10 min and the supernatants transferred to autosampler vials. 
The samples were evaporated to dryness at 50 °C under nitrogen and reconstituted in 50 µL 
water/acetonitrile/formic acid, (95:5:0.1; v/v/v). Experiments were conducted in triplicates.  
2.4 Microbial assay using fungi C. elegans 
The growth medium was prepared according to the DSMZ Medium 186 (Leibniz Institute DSMZ - 
German Collection of Microorganisms and Cell Cultures) 37. The media components containing yeast 
extract (3 g/L), malt extract (3 g/L) and peptone from soy beans (5 g/L) (solution A, without agar) and 
glucose (10 g/L) (solution B) were dissolved separately in deionized water. After autoclaving both 
solutions were mixed. For the cultivation of C. elegans, the medium (30 mL) was inoculated with a 
piece of mycelium from the agar plate. The culture flasks were shaken for three days at 100 rpm at 
28 °C on a rotary shaker (KS 260 basic, IKA-Werke GmbH & Co. Kg, Staufen im Breisgau, Germany). 
On day three, the C. elegans biomasses were transferred to new flasks containing fresh medium and 
were again inoculated with a piece of mycelium. This way, two different growth stadiums of the 
fungi biomasses were obtained, which increased the ability of the fungi to metabolise. Solutions of 
each NBOMe were prepared in 70 % ethanol with concentrations of 50 µM. On day four, 800 µL of 
NBOMe solution was added to the culture flask and incubated for 72 hours by shaking at 100 rpm at 
28 °C. In preliminary experiments, the incubation time was evaluated for time points 24, 48, 72 and 
96 hours. Results showed that 72 and 96 hours of incubation resulted equally in the most amount of 
metabolites, therefore 72 hours were chosen as incubation time. After three days, the reaction was 
stopped and the growth medium and the fungi biomass stored separately in 30 mL falcon tubes at -
20 °C, this stops the fungi‘s ability to further metabolise. Samples were stored at -20 °C until they 
were processed. Experiments were carried out in duplicates. In preliminary experiments, the growth 
medium has been analysed but only the parent compounds were detected. The reason for this is 
that the fungi only takes up the substrates in the growth medium but does not release the formed 
metabolites back to it. Therefore, for the detection and identification of metabolites in the fungi 
biomass was intensively analysed. Additionally, this made it necessary to homogenize the fungi 
biomass.  
Extractions were performed as follows: on average, 1.10 g (range 1.03-1.15 g) fungi biomass were 
weighed into a homogenization tube (gentleMacs M Tubes, Macs Miltenyi Biotec, Bergisch 
Gladbach, Germany), and 4 mL of phosphate puffer pH 9 added. The fungi sample was homogenized 
with a gentle Macs Dissociator, using a pre-programmed gradient of 45 seconds. One mL of the fungi 
solution was then transferred to a new vial and 10 µL internal standard 25B-NBOMe-D3 (2000 ng/mL) 
and 1.5 mL 1-chlorobutane added. Afterwards, the sample was mixed for at least 10 min followed by 
centrifugation for 10 min at 17’ 000 g rpm at 8 °C. The supernatant was then transferred to an 
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autosampler vial and evaporated under nitrogen at 50 °C. Finally, the sample was reconstituted in 
100 µL water/acetonitrile/formic acid (95:5:0.1; v/v/v). 
2.5 LC-HR-MS/MS analysis 
All samples were analysed using a Dionex Ultimate 3000 HPLC system (Thermo Fisher Scientific, 
Reinach, Switzerland) coupled to a 5600 TripleTof System equipped with a DuoSpray interface and 
Analyst software 1.6 TF with MasterViewTM Software Version 1.1 (Sciex, Toronto, Canada). For data 
evaluation, the following parameters were chosen: a cut-off mass error of 5 ppm, intensities higher 
than 500 cps and only peaks eluting in the gradient within 2 and 22 min. Chromatographic 
separation was performed on a reversed phase Kinetex C8 column, 2.6 µm, 100 Å, 100 x 2.1 mm 
(Phenomenex, Basel, Switzerland). The mobile phase consisted of water with 0.1 % formic acid (A) 
and acetonitrile with 0.1 % formic acid (B) with a flow rate of 0.25 mL/min. The following gradient 
was applied: 0-1 min: 2.5 % B, 1-20 min: 2.5 % to 40 % B, 20-24 min: 40-97.5 % B, 24-28 min: 97.5 % 
B, 28- 30 min: 97.5 -2.5 % B and 30-35 min: 2.5 % B. The injection volume was 1.0 µL. The MS 
parameters were as follows: ESI voltage 5.0 kV, source temperature 650 °C, curtain gas 55 arbitrary 
units, gas 1 and 2 at 55 arbitrary units. All data were acquired in positive ion mode. Information 
dependent data acquisition (IDA) was carried out using a survey scan from m/z 100 to 950, triggering 
the acquisition of product ion mass spectra for the nine most abundant precursor ions in a mass 
range from m/z 50 to 950. For dependent and survey scans the accumulation time was set to 40 ms 
and 50 ms, respectively. The collision energy was set to 35 eV and a collision energy spread of ± 15 
eV. The SCIEX QqToF system used is automatically calibrated at the start of every new 
chromatogram by injection of a calibration solution directly in the ion source (post-column). 
3. Results and Discussion 
In order to exclude matrix peaks as potential metabolites, all data obtained were compared to blank 
pHLM and fungi samples, containing the matrix but no drug and negative control samples containing 
no pHLM, respectively. The in silico predictions obtained from Meteor Nexus v.3.0.1 software 
assisted in the analysis of obtained IDA LC-HR-MS/MS scans. Extracted ion chromatograms of each 
25X-NBOMe and their metabolites are presented in Figures 1 to 3, with the upper chromatogram (A) 
belonging to the pHLM sample and the lower one (B) to the fungi C. elegans sample. The proposed 
biotransformation pathways for each compound are displayed in Figure 4 to 6. Metabolites labelled 
with (F) were present in both pHLM and C. elegans. Detailed lists of all identified metabolites are 
displayed in Tables 1 to 3.  
3.1 Identification of metabolites 
The molecular structure of 25X-NBOMe compounds and metabolites can be divided into two parts: 
the 4-substituted 2,5-dimethoxyphenethylamine is referred as the 2C part and the N-(2-
methoxybenzyl) is the so called NBOMe part 4. Figure 7 presents the nomenclature used for the 
description of fragmentation and positions of metabolisation. A large number of metabolites was 
identified for each 25X-NBOMe and therefore only the characteristic product ions used for 
identification will be discussed in detail. Representative product ion mass spectra of metabolites for 
each 25X-NBOMe are displayed in Figure 8. All other mass spectra can be found in the supporting 
information. The parent compounds and their metabolites were identified by precursor ion masses 
of the respective protonated molecule, their most abundant product ions and isotope pattern, and 
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for those metabolites occurring in both pHLM and the fungi C. elegans, by their retention times. The 
protonated masses and product ions given are the calculated values.  
For the 25X-NBOMe parent compounds, the respective precursor ions and the product ions with m/z 
121.0653 and m/z 91.5048 (representing the NBOMe part) were present. The product ions resulted 
due to amine cleavage of the NBOMe moiety forming [C8H9O]+ (m/z 121.0653) and further 
demethoxylation via neutral loss of formaldehyde forming the tropylium ion [C7H7]+(m/z 91.0548) 38. 
These product ions were consistent with previously published data on 25B-NBOMe, 25C-NBOMe and 
25I-NBOMe, because the alterations between the 25X-NBOMe are on the 2C part at the 4-position 4, 
6, 39. The following observations can be made for all metabolites of 25X-NBOMe substances: If 
product ions with m/z 121.0653 and m/z 91.0534 are present, no biotransformation occurs at the 
NBOMe part. A product ion with m/z 107.0497 is characteristic for oxidative O-demethylation at the 
2-position at the NBOMe part forming an hydroxy-cycloheptatrienylium ([C7H7O]+). A product ion 
with m/z 123.0446 ([C7H7O2]+) indicates that simultaneous oxidative O-demethylation and 
hydroxylation occurred on the NBOMe part. Hydroxylation on the NBOMe ring led to the product 
ions with m/z 137.0603 ([C8H9O2]+) in combination with a product ion with either m/z 107.0497 
([C7H7O]+) or m/z 123.0446 ([C7H7O2]+). Dihydroxylation at the NBOMe part resulted in a product ion 
with m/z 153.0552 ([C8H9O3]+). . All other product ions were specific to the 2C part and are discussed 
in the following paragraphs.  
3.1.1 25D-NBOMe  
Thirty-six distinctive 25D-NBOMe metabolites were identified in pHLM and 14 in fungi C. elegans. 
The fragmentation of the parent compound 25D-NBOMe (C19H25NO3 precursor ion M+H+ m/z 
316.1907) resulted in product ions with m/z 179.1072, m/z 121.0653, m/z 91.0538 and the 
protonated molecule with m/z 316.1900. This product ion represented amine cleavage forming 
[C11H15O2]+, and the last two are specific for the intact NBOMe part. These product ions can be used 
among others for identifying metabolites in combination with previously mentioned product ions. 
When a product ion with m/z 179.1072 ([C11H15O2]+) was present no biotransformation took place on 
the 2C part but was possible on the amine. An intact 2,5-dimethoxy-1,4-dimethyl cation was 
identified with a product ion with m/z 165.0916 ([C10H13O2]+). The three O-demethylated metabolites 
(D7-D9: C18H23NO3 precursor ion M+H+ m/z 302.1751) were differentiated depending on following 
product ions (besides the precursor ions and product ions): the occurrence of the product ions m/z 
121.0653 and m/z 91.0548 characteristic for the NBOMe part means that O-demethylation occurs on 
the 2C part, and a product ion of m/z 107.0497 ([C7H7O]+) means that O-demethylation takes place 
on the NBOMe moiety. The mono-hydroxylated in combination with O-demethylated metabolites 
(D10-D19: C18H23NO4 precursor ion M+H+ m/z 318.1700) were identified as follows: The mass 
spectrum of metabolite D10 only displays two product ions which are typical for an intact NBOMe 
part. Therefore, the only statement that can be made is that both O-demethylation and 
hydroxylation occur on the 2C part. Due to the lack of fragmentation and since tertiary hydrocarbons 
are preferred over secondary hydrocarbons as site of hydroxylation, it is more likely that 
hydroxylation occurs on the 2,5-dimethoxy-4-dimethyl 40. The fragmentation of D11 displays the loss 
of a water molecule from the precursor ion forming m/z 300.1600 ([C18H22NO3]+), which correlates 
with a rearrangement forming a double bound. Furthermore, the two characteristic NBOMe part 
product ions are present, which indicate that biotransformation must have occurred on the 2C part. 
For metabolite D12, the position of hydroxylation was narrowed down to α position or the amine 
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forming a hydroxylamine because the product ion of m/z 151.0759 ([C9H11O2]+) correlates with an α-
cleavage. The metabolite D14 has a very interesting combination of product ions, which would 
singularly point into other directions but in their combination only one structure is possible. The 
typical NBOMe part product ions are not present, which means that either O-demethylation or 
hydroxylation occurred on this part. Both, O-demethylation and hydroxylation on the NBOMe part is 
not possible because then a product ion with m/z 123.0446 ([C7H7O2]+) would be observed. The 
product ion with m/z 137.0603 ([C8H9O2]+) in combination with m/z 165.0916 ([C10H13O2]+) result 
from O-demethylation on the 2C part and are formed due to β-cleavage and amine cleavage, 
respectively. The product ion of m/z 107.0497 ([C7H7O]+) is formed by α‘-cleavage of the NBOMe 
part. For metabolite D15, the site of hydroxylation could only be narrowed down to α or β position. 
As described for D14, the product ion with m/z 123.0446 ([C7H7O2]+) can only occur when O- 
demethylation and hydroxylation are occurring combined on the NBOMe part. The product ion with 
m/z 179.1072 ([C11H15O2]+) results from amine cleavage and occurs from an intact 2C part. The 
hydroxylation is narrowed down to vicinal position. For the identification of the site of mono-
hydroxylation, several specific product ions were used (D21-D25: C19H25NO4 precursor ion M+H+ 
m/z 332.1856). Firstly, an intact 2,5-dimethoxy-4-methylphenyl moiety (therefore hydroxylation not 
taking place on this site) correlated with a product ion with m/z 180.1025 ([C10H14NO2] +). Secondly, 
hydroxylation occurring on the 2C part resulted in a product ion with m/z 210.1130 ([C11H16NO3]+), 
which could be further narrowed down with a product ion with m/z 195.1010 ([C11H15O3]+), which in 
turn specified that hydroxylation took place on the 2C part but not on the amine. The exact site of 
hydroxylation is discussed more in detail as follows: For D22, the product ion with m/z 165.0916 
([C10H13O2]+) is formed due to α-cleavage, the product ion m/z 195.1021 ([C11H15O3]+) is formed due 
to amine cleavage. On the basis of these two fragments and the typical NBOMe part fragment the 
site of hydroxylation can only be the α position. D23 and D25 have the same mass spectra. The two 
product ions with m/z 195.1021 ([C11H15O3]+), m/z 180.1025 ([C10H14NO2]+) and the two NBOMe part 
ions are formed due to α-cleavage and amine cleavage, respectively. Based on these two fragments, 
it can be concluded that hydroxylation occurs in α or β position. For metabolite D24, the position of 
the hydroxylation can be narrowed down to the vicinal position due to following fragments: The 
presence of the product ions with m/z 179.1072 ([C11H15O2]+) means that no biotransformation 
occurs on the 2C part, it is formed due to amine cleavage. The absence of the typical NBOMe part 
product ions let conclude that hydroxylation must occur on this part. And finally, the product ions 
with m/z 137.0603 ([C8H8O2]+) and m/z 107.0497 ([C7H7O]+) narrow down the site of hydroxylation to 
vicinal position because they are formed by dealkylation and α’-cleavage, respectively. The N-oxide 
metabolite D27 is eluting 0.91 min after the parent substrate, which is typical for N-oxides on 
reversed phase columns 41, and the product ions of m/z 179.1072 ([C11H15O2]+) (formed by amine 
cleavage) and the two NBOMe ions lead to the only conclusion, that it is an N-oxide. D29 is identified 
as follows: the product ion with m/z 151.0759 ([C9H11O2]+) correlates with an intact 2,5-dimethoxy-4-
methylphenyl moiety and is formed by β-cleavage. Using the two product ions with m/z 195.1021 
([C11H15O3]+) and m/z 135.0446 ([C8H7O2]+) (formed by amine cleavage and dealkylation), the sites of 
hydroxylation and oxidation of alcohols can be narrowed down to α- and vicinal position. The 
fragmentation of D30 resulted in m/z 165.0916 ([C10H13O2]+), m/z 137.0603 ([C8H8O2]+) and m/z 
107.0497 ([C7H7O]+), resulting from α-cleavage, dealkylation and α’-cleavage, respectively. Using 
these product ions the sites of hydroxylation are α and vicinal position. Metabolites D35 and D36 
have identical mass spectra. Using the product ions m/z 179.1072 ([C11H15O2]+) and m/z 153.0552 
([C8H9O3]+), which are formed by amine cleavage and dealkylation, it can be concluded that both 
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hydroxylations must occur on the NBOMe part. Furthermore, the product ion m/z 123.0446 
([C7H7O2]+), formed by α’-cleavage, determines that one hydroxylation takes place in vicinal position 
and the other one on the NBOMe ring.  
3.1.2 25E-NBOMe 
For 25E-NBOMe, 26 distinctive metabolites were identified in pHLM and 11 in the fungi C. elegans. 
The fragmentation of 25E-NBOMe (precursor ion M+H+ m/z 329.1991) resulted in product ions 
with m/z 193.1222, m/z 121.0653 and m/z 91.0534. These product ions correlated with amine 
cleavage of the 2C part forming [C12H17O2]+, and further the two specific NBOMe part product ions. 
Again, this first product ion with m/z 193.1229 ([C12H17O2]+) represented an intact 2C part 
(independent of biotransformation on the amine). When hydroxylation took place on the 2C part a 
product ion with m/z 209.1178 ([C12H17O3]+) was observed. When a product ion with m/z 181.0865 
([C10H13O3]+) was found, simultaneous double oxidative O-demethylation and hydroxylation on the 
2C part occurred. For the two identified di-O-demethylated metabolites E5 and E6 (C18H23NO3, 
precursor ion M+H+ m/z 302.1751), three different sites of O-demethylation are possible. This 
could be narrowed down by the presence (E6) or absence (E5) of the two typical NBOMe part 
product ions m/z 121.0653 and m/z 91.0534 or the product ion m/z 107.0497 ([C7H7O]+) that 
correlates with O-demethylation occurring on the NBOMe part. The mono-O-demethylation can 
occur on three different sites (E7-E9: C19H25NO3, precursor ion M+H+ m/z 316.1907). E7 and E8 had 
the same mass spectra, with the product ions m/z 179.1072 ([C11H15O2]+), m/z 121.0653 and m/z 
91.0534. These correlate with amine cleavage and the two typical NBOMe part fragments, 
respectively. E9 fragmented among others into the product ions m/z 107.0497 ([C7H7O]+), which 
stands for O-demethylation occurring on the NBOMe part and m/z 193.1229 ([C12H17O2]+) 
representing an intact 2C part. Metabolites E10 and E11 with di-O-demethylation and simultaneous 
hydroxylation (C18H23NO4 precursor ion M+H+ m/z 318.1700) displayed similar fragmentation with 
the product ions m/z 181.0865 ([C10H13O3]+) and m/z 121.0653 and m/z 91.0534, correlating with 
amine cleavage and the NBOMe part product ions. Hence, both di-O-demethylation and 
hydroxylation must occur on the 2C part. Eight different mono-O-demethylated and hydroxylated 
metabolites were detected (E12-E19: C19H25NO4, precursor ion M+H+m/z 332.1856). For metabolite 
E18 no mass spectrum was triggered, therefore no statement on its structure can be made. The sites 
of O-demethylation and hydroxylation were differentiated as follows: E14 and E19 display the same 
product ions with m/z 179.1072 ([C11H15O2]+), m/z 165.0916 ([C10H13O2]+), m/z 121.0653 and m/z 
91.0534, which are formed by amine cleavage, α-cleavage and the two typical NBOMe part 
fragments, respectively. Due to these product ions hydroxylation can only occur on the amine 
forming hydroxylamine metabolites. The mass spectra of E15 and E16 have identical predominant 
product ions with m/z 137.0603 ([C8H9O2]+) and m/z 107.0497 ([C7H7O]+), which correlate with 
mono-hydroxylation on the NBOMe ring and O-demethylation on the 2C ring. The main product ions 
used for the identification of the structure of metabolite E17 are m/z 193.1229 ([C12H17O2]+) and 
123.0446 ([C7H7O2]+), which are formed by amine cleavage and dealkylation respectively. The five 
different mono-hydroxylated metabolites (E21-E25: C20H27NO4 precursor ion M+H+ m/z 346.2013) 
were identified as follows: For metabolites E21 and E22 the same structure was identified. The mass 
spectra of E21 and E22 display the product ions m/z 209.1178 ([C12H17O3]+), m/z 179.1072 
([C11H15O2]+), and the two specific NBOMe part ions m/z 121.0653 and m/z 91.0534. The 
hydroxylation takes place at α-position due to the following observations: the product ion with m/z 
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209.1178 correlates with the hydroxylation on the 2C part and is formed by amine cleavage; the 
product ion of m/z 179.1072 can only occur when the hydroxylation does not take place on the 4-
ethyl-1-methyl-2,5-dimethoxyphenyl and is formed by α-cleavage. The mass spectrum obtained for 
E23 leads us to the conclusion that the hydroxylation must occur on the 2C part. E24 fragmentation 
resulted in product ions of m/z 193.1229 ([C12H17O2]+), m/z 137.0603 ([C8H9O2]+) and m/z 107.0497 
([C7H7O]+), correlating with dealkylation and α’-cleavage. The combination of these product ions 
unambiguously identifies the vicinal position as site of hydroxylation.  
3.1.3 25N-NBOMe 
25N-NBOMe transformation resulted in the fewest number or metabolites: 24 in total in pHLM and 9 
in fungi C. elegans. The mass spectrum of 25N-NBOMe (precursor ion M+H+ m/z 347.1601) shows 
the molecular ion and the product ions with m/z 121.0653 and m/z 91.0534. When a product ion 
with m/z 210.0766 ([C10H12NO4]+) was present, no biotransformation took place on the 2C part. 
Oxidative O-demethylation on the 2C part resulted in a product ion with m/z 196.0610 ([C9H10NO4]+). 
The metabolite resulting from the reduction of the aromatic nitro group (N8 precursor ion M+H+ 
m/z 317.1860) fragmented into m/z 180.1014 ([C10H14NO2]+), m/z 165.0781 ([C9H11NO2]+), m/z 
121.0653 and m/z 91.0534 due to cleavage of the amine, α-cleavage and the two product ions 
representing the intact NBOMe part. The site of O-demethylation occurring for metabolites N6 and 
N7 (C17H22N2O3 precursor ion M+H+ m/z 303.1703) was differentiated by the presence of the 
product ions m/z 166.0868 ([C9H12NO2]+), m/z 121.0653 and m/z 91.0534, with the first one being 
formed by amine cleavage and the two characteristic ions for NBOMe part fragments and denote O-
demethylation on the 2C part (N7). Opposed to this, the occurrence of the product ion m/z 180.1025 
([C10H14NO2]+) (also occurring for N8), which correlates with an intact 4-ethyl-2,5-dimethoxyaniline, 
implying O-demethylation taking place on the NBOMe part (N6). For metabolites N9-N11 
(C16H18N2O5 precursor ion M+H+ m/z 319.1288) the sites of di-O-demethylation were also 
differentiated by the presence (N9) or absence (N10, N11) of the NBOMe part product ions. 
Additionally, the mass spectra of N10 and N11 displayed the product ions m/z 196.0610 
([C9H10NO4]+) and m/z 107.497 ([C7H7O]+), correlating with amine cleavage and dealkylation, and can 
both only occur if O-demethylation occurs simultaneously on the 2C and NBOMe part. Nevertheless, 
the site of O-demethylation on the 2C part could not be determined. Accordingly, metabolites N12, 
N13 and N14 (C17H20N2O5 precursor ion M+H+ m/z 333.1445) were identified, with the mass spectra 
of N12 and N13 displaying the two NBOMe part product ions, and hence, O-demethylation occurring 
on the 2C part and the product ions m/z 210.0766 ([C10H12NO4]+) and m/z 107.497 ([C7H7O]+), which 
can only occur if the 2C part is intact and O-demethylation taking place on the NBOMe part, 
respectively. The O-demethylated and hydroxylated metabolites (N15-N18: C17H20N2O6 precursor ion 
M+H+ m/z 349.1394) were identified by using mainly the NBOMe part fragments and the product 
ions m/z 137.0603 ([C8H9O2]+), m/z 123.0446 ([C7H7O2]+), the exact site of hydroxylation was 
determined as follows: The predominant product ions in the mass spectrum of N15 m/z 210.0766 
([C10H12NO4]+) and m/z 123.0446 ([C7H7O2]+), are formed by amine cleavage and dealkylation. It can 
be concluded that the 2C part is intact and that both O-demethylation and hydroxylation must occur 
on the NBOMe part. The mass spectrum of N16 resulted in very little fragmentation with the 
precursor ion m/z 349.1394 and two product ions m/z 121.0653 and m/z 91.0534. Therefore, it was 
only possible to conclude the site of O-demethylation to be on the 2C part. Due to the absence of 
further product ions it is more likely that the hydroxylation also occurs on the 2,5-dimethoxy-4-
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nitrophenyl. For N17 the fragmentation was similar, with the precursor ion and two product ions 
m/z 137.0603 ([C8H9O2]+) and m/z 123.0446 ([C7H7O2]+). Hence, O-demethylation must occur on the 
NBOMe part. The site of hydroxylation could only be narrowed down to the NBOMe part. Due to the 
absence of product ions formed by α and β cleavage it is more likely that the hydroxylation occurs on 
the 2,5-dimethoxy-4-nitrophenyl. The mass spectrum of N18 was a bit more complicated to 
interpret. N18 fragmented into the following product ions m/z 227.1026 ([C10H15N2O4]+), m/z 
210.0766 ([C10H12N2O4]+), m/z 195.0532 ([C9H9NO4]+), m/z 137.0603 ([C8H9O2]+) and m/z 123.0446. 
These are formed by dealkylation, amine cleavage, a further loss of a methyl radical and 
dealkylation, respectively 42. Hencem both O-demethylation and hydroxylation must occur on the 2C 
part. The fragmentation of N19 (C20H26N2O4 precursor ion M+H+ m/z 359.1965) displayed the 
following product ions: m/z 237.1239 ([C12H17N2O3]+), m/z 222.1130 ([C12H16NO3]+), m/z 121.0653 
and m/z 91.0534, which are formed by dealkylation and amine cleavage, respectively. The mass 
spectrum of N20 (C18H20N2O6 precursor ion M+H+ m/z 359.1965) showed very little fragmentation 
with the two NBOMe part ions and product ion m/z 239.0668 ([C10H11N2O5]+), the latter being 
formed by dealkylation. Therefore, the oxidation of secondary alcohols can only occur on α- or β-
position. The identification of the structures of the mono-hydroxylated metabolites N21- N24 
(C18H22N2O6 precursor ion M+H+ m/z 363.1551) is more complicated due to little fragmentation. 
Metabolite N21 fragmented into the two NBOMe part product ions and therefore the hydroxylation 
must occur on the 2C part. It is eluting 1.66 min after the parent substrate and is consequently 
identified as an N-oxide metabolite. N-oxides typically elute after the parent substrate on a reverse 
phase column 27, 41. The fragmentation of N22 displayed the product ions m/z 345.1450 
([C18H21N2O5]+), m/z 121.0653 and m/z 91.0534. The first one is formed by cleavage of the hydroxyl 
on the amine and the rearrangement forming a double bound. Therefore N22 was identified to be a 
hydroxylamine metabolite. The position of hydroxylation of N23 and N24 was identified to be 5 
position on the NBOMe part ring using the product ions m/z 137.0603 ([C8H9O2]+), m/z 109.0645 
([C6H5O2]+), and m/z 107.0485 correlating with dealkylation, simultaneous cleavage of the NBOMe 
ring and the methyl on the methoxy group forming a protonated chinone.  
3.2 Microsomal biotransformation 
Incubation of pHLM with 25D-NBOMe, 25E-NBOMe and 25N-NBOMe resulted in 36, 26 and 24 
metabolites, respectively. Several different biotransformational mechanisms were observed in all 
three 25X-NBOMe compounds. Hydroxylation of the parent substrate (+15.995 Da) formed six 25D-
NBOMe metabolites (D21-D26), five 25E-NBOMe metabolites (E21-E25) and three 25N-NBOMe 
metabolites (N22-N24). Hydroxylation of the parent compound was observed at α-position for D22, 
E21 and E22, β- or α-position for D23, D25 and α-position or on the amine for D26, E23, E25 and 
N22. D23, D25 and N22 were further metabolised by oxidation of the secondary alcohol forming D20 
and N20. For both D24 and E24 hydroxylation was identified to be on the vicinal position. Two N-
oxide metabolites were observed (D27/ N21) both eluting after the parent substrates, which is 
typical for N-oxides on reversed phase columns 27, 41. The resulting mono-hydroxylated metabolites 
underwent further oxidative O-demethylation (D10-D19/ E12-E19/ N15-N18; mass difference to 
parent substrate -14.0157 Da) on the 2C part (D10-D12, D14, D15, D17, D19/ E12-E16, E19/ N16) or 
on the NBOMe part (D16/ E17 / N15, N17, N18). Oxidative O-demethylation of the parent compound 
(mass difference to parent -14.0156 Da) on either the 2nd or 5th position of the 2C part or 2nd position 
on the NBOMe part was observed for all three compounds resulting in three metabolites (D7/ E8/ 
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N12; D8/ E7/ N13; D9/ E9/ N14;). Further oxidative O-demethylation (mass difference to parent 
substrate -28.0312 Da) of these metabolites resulted in metabolites found for all three tested 25X-
NBOMes (D4/ E6/ N9; D5/ E5/ N10; D6/ N11;). Only for E6 further metabolisation occurred, forming 
a di-O-demethylated and hydroxylated metabolite E10 and E11. For all three substrates, the 
respective 2,5-dimethoxyphenethylamine (2C-X) metabolites could be identified (D2, E3, N3) formed 
by oxidative N-dealkylation (-120.0575 Da). 2C-X are also biologically active compounds used for 
recreational purposes and have been previously identified as 25B-NOMe and 25I-NBOMe 
metabolites 4. This 2C-X metabolite was further metabolised by oxidative deamination forming 2-
methoxybenzoic acid (D1/ E1/ N1; precursor ion M+H+ m/z 153.0546), identical for all three 
substrates. For 25E-NBOMe and 25N-NBOMe E3 and N3 were further metabolised by oxidative O-
demethylation to E2 and N2 (precursor ion M+H+ m/z 196.1332 and m/z 213.0870). The 25D-
NBOMe and 25E-NBOMe 2C-X metabolites were hydroxylated forming D3 and E4. For metabolites 
D27 (precursor ion M+H+ m/z 346.1649) and E26 (precursor ion M+H+ m/z 360.1806) 
carboxylation of the primary alcohol or alkyl was observed, respectively.  
Biotransformation of 25E-NBOMe and 25D-NBOMe was very similar. However, 25D-NBOMe 
produced seven additional dihydroxylated metabolites (D30-36, precursor ion M+H]+ m/z 
348.1806), which could neither be found for 25E-NBOMe nor for 25N-NBOMe. Sites of 
dihydroxylation were for D30 in α and vicinal position, for which in vicinal position oxidation of a 
primary alcohol took place. Metabolites D31 and D32 had the hydroxylations taking place on the 2C 
ring and in α-position (D32) or β-position (D31). Whereas for D33 it could be undoubtedly 
determined that a hydroxylamine was formed and a second hydroxylation took place in α-position. 
Metabolites D35 and D36 had hydroxylation occurring on the NBOMe ring and in vicinal position. 
Unique 25N-NBOMe metabolites were formed due to reduction of the aromatic nitro group at the 4-
position (N8, precursor ion M+H+ m/z 317.1860), which was further metabolised by oxidative O-
demethylation (N6, N7, precursor ion M+H+ m/z 303.1703), or N-acetylation of the primary 
aromatic amine (N19, precursor ion M+H+ m/z 359.1965).  
In summary, the observed biotransformation pathways of 25D-NBOMe were oxidative O-
deamination, oxidative N-dealkylation also in combination with hydroxylation, oxidative O-
demethylation possibly combined with hydroxylation, oxidation of secondary alcohols, mono- and 
dihydroxylation, oxidation of primary alcohols and carboxylation of primary alcohols. For 25E-
NBOMe the same metabolism steps were observed differing in the sites of metabolic modifications. 
Additionally, oxidative di-O-demethylation was seen. 25N-NBOME metabolism was very similar to 
25D-NBOMe and 25E-NBOMe, with mostly the same steps observed. In addition, due to the 
presence of the aromatic nitro group, the following mechanisms were observed: reduction of the 
aromatic nitro group, also in combination with demethylation and N-acetylation of the primary 
aromatic amine.  
Meteor Nexus was a helpful aid in the evaluation of obtained IDA-LC-HR-MS/MS data in combination 
with the MasterViewTM software. Nevertheless, a critical interpretation of data is necessary using 
described parameters. Every hit passing this criterion must then be manually checked if the peak 
was a peak or simply noise and if the isotopic ratio was correct. The mass spectra are then used to 
unambiguously identify a metabolite. Only 19 metabolites were not predicted by Meteor Nexus but 
identified by the authors using the gained knowledge about typical fragmentation patterns. 
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Therefore, the in silico predictions provided by Meteor Nexus are a valuable tool for data evaluation 
but nevertheless need to be assessed critically.  
Caspar et al. 4 reported 35 phase I metabolites of 25B-NBOMe of which 13 followed the same 
biotransformation pathways as 35 metabolites of the 90 metabolites found for 25D-NBOMe, 25E-
NBOMe and 25N-NBOMe. N-oxides and hydroxylamines of 25X-NBOMes were identified in the 
present study , which have not yet been reported in literature.  
3.3 Microbial biotransformation 
Microbial experiments incubations of 25D-NBOMe, 25E-NBOMe or 25N-NBOMe with C. elegans 
generated 14, 11 and 9 metabolites, respectively. Each metabolite found in fungi was also identified 
in pHLM. Metabolites were identified according to their precursor ion, fragmentation , isotope ratios 
and retentions times, which were the same as for the metabolites found in previous experiments 
with pHLM. Biotransformation steps observed in fungi C. elegans were oxidative N-dealkylation, 
oxidative O-demethylation also in combination with hydroxylation, oxidation of secondary alcohols 
and mono- and di-hydroxylation for all three compounds, and for 25N-NBOMe additionally 
reduction of the aromatic nitro groups and N-hydroxylation of secondary aliphatic amines. For 25D-
NBOMe and 25N-NBOMe also N-oxide formation and hydroxylamine metabolites were identified.  
The microsomal method of pHLM generated three times more metabolites than the microbial 
method of the fungi C. elegans. Watanabe et al.32 reported to have found more metabolites of JWH-
018 and other similar synthetic cannabinoids, in C. elegans than literature data reports found in 
pHLM. But Watanabe et al. used a different C. elegans line, which could explain different results. The 
ability of the fungi C. elegans to metabolise xenobiotics and especially NPS could depend on the 
chemical class of the drug. Therefore, it is advised to conduct more metabolism studies with C. 
elegans, investigating different chemical classes of NPS, in order to be able to conclude the fungi’s 
ability to be a good metabolism model.  
4 Conclusion  
Microsomal and microbial experiments resulted in thirty-six 25D-NBOMe phase I metabolites, 
twenty-six 25E-NBOMe phase I metabolites and twenty-four 25N-NBOMe phase I metabolites. One 
metabolite identical for all three compounds was found (E1/ D1/ N1). For the first time, an N-oxide 
25X-NBOMe metabolite was identified, namely D27 and N21, which eluted 0.91 min and 1.66 min 
after the parent substrate, respectively. Additionally, hydroxylamine metabolites were identified due 
to their fragmentation (D11, D12, D17, D26, D33; E12, E13, E14, E19, E23, E25; N22). For 25N-
NBOMe unique metabolites were detected due to the reduction of the aromatic nitro group. Main 
biotransformation steps observed were oxidative O-demethylation, mono and dihydroxylation, N-
oxide formation, hydroxylamine formation and N-dealkylation. Additionally, metabolites found in 
both pHLM and fungi C. elegans were eluting at the same retention times and could therefore be 
identified according their retention times. The fungi C. elegans could generate all main phase I 
biotransformation steps observed for all three compounds and therefore is an interesting model for 
further studies of NPS metabolism. Nevertheless, in the current study no phase II metabolites were 
identified in the fungi C. elegans samples. When authentic biological samples of consumers of 25D-
NBOMe, 25E-NBOMe or 25N-NBOMe are available, these metabolites can be used for target 
analysis, and might confirm the predictions from in-vitro experiments to some extent. Additionally, 
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phase II metabolites (e.g. glucuronides) might be present in urine samples, which might have similar 
mass spectrometric product ions.  
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Table 1 Identified metabolites of 25D-NBOMe in pHLM and Fungi C. elegans sorted by their protonated mass [M+H]+. The three most abundant product ions 
of 25D-NBOMe and its metabolites are listed with their relative intensities (percentage of the base peak intensity) as indices numbers.  
Name Biotransformation Formula 
[M+H]+ 
[] 
pHLM Fungi C. elegans Product ions 
[m/z] and ion 
ratios [%] 
error [ppm] RT [min] Intensity [cps] error [ppm] RT [min] Intensity [cps] 
D1 Oxidative 
deamination 









































C18H23NO3 302.1751 0.3 15.48 161'255 0.0 15.53 21'765 179.1068100 
164.083140 
107.048930 
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C18H23NO4 318.1700 -0.2 15.07 1'461    121.0636100 
91.054730 
93.070520 
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D20 Oxidation of 
Secondary 
Alcohols 






























C19H25NO4 332.1856 0.6 16.04 61'417 1.0 16.09 38'829 314.175340 
121.0640100 
91.053818 
D27 N-oxide formation C19H25NO4 332.1856 0.6 18.29 8'220 0.6 18.31 2'860 179.107435 
121.0640100 
91.053828 
D28 Carboxylation  of 
Primary Alcohol 
C19H23NO5 346.1649 -0.6 12.40 37'481    121.0639100 
93.068610 
91.053520 
D29 Oxidation of 
Primary Alcohols 
C19H23NO5 346.1649 0.7 16.6 10'705    195.1015100 
180.077338 
135.080228 
D30 dihydroxylation C19H25NO5 348.1806 -0.1 10.70 42'259    165.090621 
137.0594100 
107.047626 
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D31 Dihydroxylation C19H25NO5 348.1806 0.8 11.36 5'865    330.169931 
121.0640100 
91.053320 
D32 Dihydroxylation C19H25NO5 348.1806 0.6 11.59 1'516    181.083515 
121.0638100 
91.054320 
D33 Dihydroxylation C19H25NO5 348.1806 0.3 13.41 4'722 -0.4 13.52 984 165.090745 
121.0640100 
91.053420 
D34 Dihydroxylation C19H25NO5 348.1806 1 13.85 3'409    No MS2 
triggered 
D35 Dihydroxylation C19H25NO5 348.1806 -0.9 14.00 7'535    193.133935 
179.1067100 
153.054975 
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Table 2 Identified metabolites of 25E-NBOMe identified in pHLM and fungi C. elegans sorted by their protonated  mass [M+H]+.  
Name Biotransformation Sum formula 
[M+H]+  
[m/z] 
pHLM Fungi C. elegans Product ions 
[m/z] and ion 
ratios [%] 















































C19H25NO3 316.1907 -0.3 17.52 155'849 -0.5 17.52 73'875 193.1226100 
178.099035 
107.049027 










C18H23NO4 318.1700 0.4 12.37 7'251    181.083835 
121.0639100 
91.053030 














































C19H25NO4 332.1856 0.4 16.91 1'259    179.108222 
121.0642100 
98.982530 
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E20 Oxidation of alkyl 
chain 

























C20H27NO4 346.2013 0 17.98 52'036 -0.8 18.02 30'785 328.190640 
121.0640100 
91.053520 
E26 Carboxylation of 
alkyl 





 This article is protected by copyright. All rights reserved. 
Table 3 Metabolites of 25N-NBOMe identified in pHLM and fungi C. elegans samples sorted by the mass of the protonated molecule [M+H]+.  
Name Biotransformation Formula 
[M+H]+ 
[m/z] 
pHLM Fungi C. elegans Product ions 




RT [min] Intensity [cps] error [ppm] RT [min] Intensity [cps] 
N1 Oxidative 
deamination 






























C17H22N2O3 303.1703 0.6 7.04 4'846    166.0858100 
121.064370 
91.053233 
N8 Reduction of 
Aromatic Nitro 
Groups 





C16H18N2O5 319.1288 -1 12.69 7'906    121.0640100 
93.06937 
91.053823 
N10 Oxidative di-O- C16H18N2O5 319.1288 -0.6 13.00 4'555    213.0686075 




















C17H20N2O5 333.1445 0.9 13.84 230'815 -0.1 13.87 32'874 227.103462 
210.076375 
107.0489100 
























C17H20N2O6 349.1394 0.4 11.35 29'809    227.102160 
210.076267 
123.0434100 
N19 N-Acethylation of 
Primary Aromatic 
Amine 
C20H26N2O4 359.1965 0.6 12.92 4'080    222.112540 
180.099923 
121.0636100 
N20 Oxidation of C18H20N2O6 361.1394 0.5 13.30 3'800    239.06755 
 This article is protected by copyright. All rights reserved. 
Secondary Alcohol 121.0638100 
91.053022 















C18H22N2O6 363.1551 0 13.68 283'892 -0.2 13.71 1'878 137.0606100 
109.067330 
107.058425 
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Figure 1: Extracted ion chromatogram of 25D-NBOMe and its metabolites after pHLM incubation 
with 25D-NBOMe (A). Extracted ion chromatogram of 25D-NBOMe and its metabolites after fungi C. 
elegans incubation with 25D-NBOMe (B). 
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Figure 2 Extracted ion chromatogram of 25-NBOMe and its metabolites after pHLM (2A) and fungi C. 
elegans (2C) incubation with 25E-NBOMe. 
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Figure 3 Extracted ion chromatogram of 25N-NBOMe and its metabolites after pHLM (3A) and fungi 
C. elegans (3B) incubation with 25N-NBOMe. For both pHLM and fungi C. elegans an N-oxide 
metabolite (N21) eluted after the parent compound.   
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Figure 4 Proposed biotransformation pathway of 25D-NBOMe. Metabolites labelled with (F) were 
found in both pHLM and fungi C. elegans samples. For structures in brackets the exact site of 
biotransformation could not be determined.  
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Figure 5 Suggested biotransformation pathway of 25E-NBOMe. Metabolites labelled with (F) were 
found in both pHLM and fungi C. elegans samples. In brackets: exact site of biotransformation could 
not be determined 
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Figure 6 Proposed biotransformation pathway of 25N-NBOMe. Metabolites labelled with (F) were 
identified in pHLM and fungi C. elegans. In brackets: exact site of biotransformation could not be 
determined.  
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Figure 7 Nomenclature used for the identification of metabolites. 
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Figure 8 Representative product ion spectra of 25D-NBOMe (A, B, C, D), 25E-NBOMe (E, F, G, H) and 
25N-NBOMe (I, J, K) metabolites after incubation in pHLM and fungi C. elegans. Fragmentation was 
selected for the ten most abundant precursor ions with CE of 35 eV with a CES of ±15 eV.  
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